Clinical Report: Evaluating the Diagnostic Performance of Surveillance Methods for Hepatocellular Carcinoma in Cirrhotic Patients

Overview

This systematic review and network meta-analysis evaluated the diagnostic accuracy of various surveillance methods for hepatocellular carcinoma (HCC) in patients with cirrhosis.

Background

Hepatocellular carcinoma (HCC) is a significant cause of cancer-related morbidity and mortality, particularly in patients with cirrhosis. Effective surveillance is critical for early detection and treatment of HCC. This study synthesizes evidence from multiple tests to inform optimal surveillance strategies.

Data Highlights

This systematic review included 170 studies with 62,643 participants, evaluating 115 index tests for HCC detection in cirrhotic patients.

Key Findings

• Ultrasound and alpha-fetoprotein have similar sensitivity for very-early-stage HCC (0.34 vs 0.39).
• Contrast-enhanced MRI shows higher sensitivity across stages: 0.70 for very-early, 0.86 for early, and 0.90 for advanced HCC.
• CT sensitivity is also stage-dependent: 0.68 for very-early, 0.77 for early, and 0.92 for advanced HCC.
• No genomic biomarkers demonstrated significant improvements over conventional blood markers.
• Most studies included in the review were assessed to be at high risk of bias.
• Combining ultrasound with alpha-fetoprotein may improve sensitivity for early-stage detection.

Clinical Implications

Clinicians should consider the limitations of existing surveillance tools.

Conclusion

The study indicates a need for better diagnostic strategies for early-stage HCC in cirrhotic patients.

Related Resources & Content

1. JAMA Network Open, 2023 -- Pandemic-Related Disruptions and Hepatocellular Carcinoma Surveillance in Safety-Net Settings
2. Journal of Gastroenterology, 2013 -- Early Detection of Hepatocellular Carcinoma Through High-Sensitivity Alpha-Fetoprotein Assay Using Lens culinaris Agglutinin Reactivity
3. The New Gastroenterologist, 2025 -- Enhanced Risk Assessment Tool May Optimize HCC Monitoring in Cirrhosis Patients
4. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma, 2025
5. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, 2025
6. Assessment of Prognostic Factors in Surgical Resection for Hepatocellular Carcinoma: A Comparative Study of Eight Staging Systems
7. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
8. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
9. A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis - PubMed
10. Comparison of abbreviated MRI and ultrasonography in the detection of early hepatocellular carcinoma: a meta-analysis - PubMed
11. Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis | Hepatobiliary Disease | JAMA Oncology | JAMA Network